Matches in Wikidata for { <http://www.wikidata.org/entity/Q64189599> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- Q64189599 description "clinical trial" @default.
- Q64189599 description "ensayu clínicu" @default.
- Q64189599 description "klinisch onderzoek" @default.
- Q64189599 description "клінічне випробування" @default.
- Q64189599 name "To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy." @default.
- Q64189599 type Item @default.
- Q64189599 label "To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy." @default.
- Q64189599 prefLabel "To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy." @default.
- Q64189599 P1132 Q64189599-035B2B49-1F7A-41A5-BDBA-79F30EC37ADF @default.
- Q64189599 P1476 Q64189599-838CA175-8FE6-4A62-9DC3-EA1840056159 @default.
- Q64189599 P17 Q64189599-02F36E81-A558-4002-B67B-D0E30A26DA16 @default.
- Q64189599 P17 Q64189599-0622667D-6D72-4DB4-A5DA-5C8F987C3A6C @default.
- Q64189599 P17 Q64189599-16A98D64-31C4-436E-8160-AC2489BB1B9F @default.
- Q64189599 P17 Q64189599-292BBA9B-05E8-47CA-8B90-F5B6F7A30B24 @default.
- Q64189599 P17 Q64189599-48A3E5C3-A546-4750-9E9C-E29EB8B7E43D @default.
- Q64189599 P17 Q64189599-70708F55-8F9E-45DB-95A2-3483984EBBB2 @default.
- Q64189599 P17 Q64189599-7214E080-A115-449D-AA6A-78E7F96213F3 @default.
- Q64189599 P17 Q64189599-7BE461FD-524D-46C9-BA5D-06DA529342CE @default.
- Q64189599 P17 Q64189599-9A8A7D5E-E69E-4B71-A9E0-78D93FD26119 @default.
- Q64189599 P17 Q64189599-9B0CA206-45D8-4751-BB10-3066F10B8416 @default.
- Q64189599 P17 Q64189599-BAF929F2-F261-4ED6-AE0B-A21932C0DEA8 @default.
- Q64189599 P17 Q64189599-E13CAD86-1DF2-43F2-A6AA-1BB3DE9112AC @default.
- Q64189599 P17 Q64189599-ECE7DC34-0668-4E86-9161-A8288A6EF689 @default.
- Q64189599 P2899 Q64189599-4125B57E-9A24-4F92-B2DD-759EEEE418F5 @default.
- Q64189599 P3098 Q64189599-CEA92233-5473-4722-9001-73B6F7EA68E6 @default.
- Q64189599 P31 Q64189599-A503911E-3C3C-46C3-9E45-B0399825FB0F @default.
- Q64189599 P4135 Q64189599-795FA624-A1FE-4813-9058-58857D590909 @default.
- Q64189599 P4844 Q64189599-BD0AFFBF-CD00-4E14-9FF5-199E55498738 @default.
- Q64189599 P580 Q64189599-9EDE951E-FBF5-46F6-B5A6-D89D490BBF25 @default.
- Q64189599 P582 Q64189599-9762252E-63C9-413D-AA1C-C707E30E3087 @default.
- Q64189599 P6099 Q64189599-9A7E8771-1432-4F05-BA70-C8E9AA1D1F7C @default.
- Q64189599 P8363 Q64189599-595E5EC2-0B56-4C6C-9915-D877BDD5355D @default.
- Q64189599 P1132 "+450" @default.
- Q64189599 P1476 "A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination With Olaparib Versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-Related Genes (Including BRCA1/2) (VIOLETTE)." @default.
- Q64189599 P17 Q142 @default.
- Q64189599 P17 Q145 @default.
- Q64189599 P17 Q16 @default.
- Q64189599 P17 Q183 @default.
- Q64189599 P17 Q27 @default.
- Q64189599 P17 Q29 @default.
- Q64189599 P17 Q30 @default.
- Q64189599 P17 Q31 @default.
- Q64189599 P17 Q36 @default.
- Q64189599 P17 Q38 @default.
- Q64189599 P17 Q45 @default.
- Q64189599 P17 Q55 @default.
- Q64189599 P17 Q865 @default.
- Q64189599 P2899 "+18" @default.
- Q64189599 P3098 "NCT03330847" @default.
- Q64189599 P31 Q30612 @default.
- Q64189599 P4135 "+130" @default.
- Q64189599 P4844 Q27074716 @default.
- Q64189599 P580 "2018-02-21T00:00:00Z" @default.
- Q64189599 P582 "2021-01-20T00:00:00Z" @default.
- Q64189599 P6099 Q42824440 @default.
- Q64189599 P8363 Q78089383 @default.